These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 3315186)

  • 1. Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck.
    Heo DS; Whiteside TL; Johnson JT; Chen KN; Barnes EL; Herberman RB
    Cancer Res; 1987 Dec; 47(23):6353-62. PubMed ID: 3315186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes.
    Wang YL; Si LS; Kanbour A; Herberman RB; Whiteside TL
    Cancer Res; 1989 Nov; 49(21):5979-85. PubMed ID: 2507139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian tumors.
    Heo DS; Whiteside TL; Kanbour A; Herberman RB
    J Immunol; 1988 Jun; 140(11):4042-9. PubMed ID: 3286766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytolytic antitumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes in recombinant interleukin 2.
    Whiteside TL; Heo DS; Takagi S; Johnson JT; Iwatsuki S; Herberman RB
    Cancer Immunol Immunother; 1988; 26(1):1-10. PubMed ID: 3257898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.
    Belldegrun A; Muul LM; Rosenberg SA
    Cancer Res; 1988 Jan; 48(1):206-14. PubMed ID: 3257161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro generation and antitumor activity of adherent lymphokine-activated killer cells from the blood of patients with brain tumors.
    Whiteside TL; Wang YL; Selker RG; Herberman RB
    Cancer Res; 1988 Nov; 48(21):6069-75. PubMed ID: 2971433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of novel anti-tumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes.
    Whiteside TL; Heo DS; Takagi S; Herberman RB
    Transplant Proc; 1988 Apr; 20(2):347-50. PubMed ID: 2834838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enrichment in tumor-reactive CD8+ T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer.
    Letessier EM; Heo DS; Okarma T; Johnson JT; Herberman RB; Whiteside TL
    Cancer Res; 1991 Aug; 51(15):3891-9. PubMed ID: 1677310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma.
    Finke JH; Rayman P; Alexander J; Edinger M; Tubbs RR; Connelly R; Pontes E; Bukowski R
    Cancer Res; 1990 Apr; 50(8):2363-70. PubMed ID: 2107973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas.
    Itoh K; Tilden AB; Balch CM
    Cancer Res; 1986 Jun; 46(6):3011-7. PubMed ID: 3486040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors.
    Miescher S; Whiteside TL; Moretta L; von Fliedner V
    J Immunol; 1987 Jun; 138(11):4004-11. PubMed ID: 3108380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
    Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
    Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
    Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
    J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypical and functional differences of tumor-infiltrating lymphocytes from human colorectal cancers induced by costimulation with rIL-2 and rIL-4 in vitro.
    Keller H; Wimmenauer S; Rahner S; Von Kleist S; Farthmann EH
    Anticancer Res; 1996; 16(6B):3565-70. PubMed ID: 9042222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clonal analysis of lymphocytes from tumor, peripheral blood, and nontumorous kidney in primary renal cell carcinoma.
    Kim TY; von Eschenbach AC; Filaccio MD; Hayakawa K; Parkinson DR; Balch CM; Itoh K
    Cancer Res; 1990 Sep; 50(17):5263-8. PubMed ID: 2143685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antitumor activity of human tumor infiltrating lymphocytes (TIL) and its comparison with peripheral blood lymphocytes (PBL)].
    Xu ZY
    Zhonghua Zhong Liu Za Zhi; 1990 Sep; 12(5):345-7. PubMed ID: 2177396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma.
    Reichert TE; Strauss L; Wagner EM; Gooding W; Whiteside TL
    Clin Cancer Res; 2002 Oct; 8(10):3137-45. PubMed ID: 12374681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
    Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
    Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Functional and phenotypic analysis of tumor infiltrating lymphocytes derived from solid tumors and effusion associated lymphocytes in malignant ascites cultured in recombinant interleukin 2].
    Itoh K; Shiiba K; Ebina N; Anzai R; Ouchi A; Matsuno S
    Nihon Geka Gakkai Zasshi; 1993 Aug; 94(8):781-90. PubMed ID: 8377752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors.
    Alexander JP; Kudoh S; Melsop KA; Hamilton TA; Edinger MG; Tubbs RR; Sica D; Tuason L; Klein E; Bukowski RM
    Cancer Res; 1993 Mar; 53(6):1380-7. PubMed ID: 8443817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.